Market Cap
US$381.5m
Last Updated
2020/07/04 23:51 UTC
Data Sources
Company Financials +
Executive Summary
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Limited growth with weak fundamentals.
Share Price & News
How has MannKind's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MNKD's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
3.5%
MNKD
3.1%
US Biotechs
4.0%
US Market
1 Year Return
55.7%
MNKD
24.3%
US Biotechs
4.9%
US Market
Return vs Industry: MNKD exceeded the US Biotechs industry which returned 24.2% over the past year.
Return vs Market: MNKD exceeded the US Market which returned 5% over the past year.
Shareholder returns
| MNKD | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.5% | 3.1% | 4.0% |
| 30 Day | 26.1% | 7.3% | 1.3% |
| 90 Day | 90.4% | 31.2% | 29.5% |
| 1 Year | 55.7%55.7% | 25.5%24.3% | 7.2%4.9% |
| 3 Year | 53.0%53.0% | 32.8%28.4% | 36.1%27.2% |
| 5 Year | -93.3%-93.3% | 0.04%-5.7% | 65.3%46.9% |
Price Volatility Vs. Market
How volatile is MannKind's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
How Much Did MannKind Corporation's (NASDAQ:MNKD) CEO Pocket Last Year?5 months ago | Simply Wall St
Imagine Owning MannKind (NASDAQ:MNKD) And Taking A 96% Loss Square On The Chin7 months ago | Simply Wall St
Is MannKind Corporation's (NASDAQ:MNKD) CEO Overpaid Relative To Its Peers?Valuation
Is MannKind undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether MannKind is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MannKind has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at our analysis of MNKD’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
Future Growth
How is MannKind forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
66.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MNKD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MNKD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MNKD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MNKD's revenue (26.1% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: MNKD's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MNKD's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has MannKind performed over the past 5 years?
24.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MNKD is currently unprofitable.
Growing Profit Margin: MNKD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MNKD is unprofitable, but has reduced losses over the past 5 years at a rate of 24.8% per year.
Accelerating Growth: Unable to compare MNKD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MNKD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: MNKD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is MannKind's financial position?
Financial Position Analysis
Short Term Liabilities: MNKD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MNKD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MNKD has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MNKD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MNKD has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MNKD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 0.5% each year
Next Steps
Dividend
What is MannKind current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MNKD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MNKD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MNKD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MNKD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MNKD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.4yrs
Average management tenure
CEO
Michael Castagna (43yo)
3.17yrs
Tenure
US$1,551,765
Compensation
Dr. Michael E. Castagna, Pharm.D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016 ...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD1.55M) is about average for companies of similar size in the US market ($USD2.15M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.17yrs | US$1.55m | 0.098% $374.1k | |
| Chief Financial Officer | 3yrs | US$937.85k | 0.0027% $10.3k | |
| Executive VP | 18.5yrs | US$988.41k | 0.13% $487.9k | |
| Chief Commercial Officer | 3yrs | US$921.51k | 0.026% $98.7k | |
| Chief Medical Officer | 2.42yrs | US$1.01m | 0.029% $110.3k | |
| Chief Technology Officer | 4.75yrs | US$707.89k | 0.010% $39.3k | |
| VP of Investor Relations & Treasury | no data | US$519.59k | 0.017% $66.5k | |
| Chief People & Workplace Officer | 3.58yrs | US$1.04m | 0.049% $187.4k | |
| Senior Vice President of Worldwide Regulatory Affairs | 14.75yrs | no data | no data |
3.4yrs
Average Tenure
56yo
Average Age
Experienced Management: MNKD's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.17yrs | US$1.55m | 0.098% $374.1k | |
| Independent Director | 16.75yrs | US$169.49k | 0.055% $211.0k | |
| Independent Chairman | 4.42yrs | US$196.99k | 0.13% $510.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 16.58yrs | US$162.69k | 0.034% $128.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
10.5yrs
Average Tenure
74.5yo
Average Age
Experienced Board: MNKD's board of directors are seasoned and experienced ( 10.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MNKD insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.5%.
Top Shareholders
Company Information
MannKind Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: MannKind Corporation
- Ticker: MNKD
- Exchange: NasdaqGM
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$381.517m
- Shares outstanding: 213.14m
- Website: https://www.mannkindcorp.com
Number of Employees
Location
- MannKind Corporation
- 30930 Russell Ranch Road
- Suite 300
- Westlake Village
- California
- 91362
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MNKD | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Jul 2004 |
| NNFN | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2004 |
Biography
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/04 23:51 |
| End of Day Share Price | 2020/07/02 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.